Why clinical translation cannot succeed without failure

The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider r...

Descripción completa

Detalles Bibliográficos
Autores principales: London, Alex John, Kimmelman, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2015
Materias:
Human Biology and Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657068/
https://www.ncbi.nlm.nih.gov/pubmed/26599839
http://dx.doi.org/10.7554/eLife.12844
_version_ 1782402329261113344
author London, Alex John
Kimmelman, Jonathan
author_facet London, Alex John
Kimmelman, Jonathan
author_sort London, Alex John
collection PubMed
description The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider recognition of these benefits will help the biomedical research enterprise to take full advantage of all the information generated during the drug development process.
format Online
Article
Text
id pubmed-4657068
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-46570682015-11-25 Why clinical translation cannot succeed without failure London, Alex John Kimmelman, Jonathan eLife Human Biology and Medicine The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider recognition of these benefits will help the biomedical research enterprise to take full advantage of all the information generated during the drug development process. eLife Sciences Publications, Ltd 2015-11-24 /pmc/articles/PMC4657068/ /pubmed/26599839 http://dx.doi.org/10.7554/eLife.12844 Text en © 2015, London and Kimmelman http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Human Biology and Medicine
London, Alex John
Kimmelman, Jonathan
Why clinical translation cannot succeed without failure
title Why clinical translation cannot succeed without failure
title_full Why clinical translation cannot succeed without failure
title_fullStr Why clinical translation cannot succeed without failure
title_full_unstemmed Why clinical translation cannot succeed without failure
title_short Why clinical translation cannot succeed without failure
title_sort why clinical translation cannot succeed without failure
topic Human Biology and Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657068/
https://www.ncbi.nlm.nih.gov/pubmed/26599839
http://dx.doi.org/10.7554/eLife.12844
work_keys_str_mv AT londonalexjohn whyclinicaltranslationcannotsucceedwithoutfailure
AT kimmelmanjonathan whyclinicaltranslationcannotsucceedwithoutfailure

Ejemplares similares